iiinova — where your digital self keeps evolving

Dana-Farber Cancer Institute @danafarber.bsky.social · 01/10/2026

Congratulations to @sidujain.bsky.social, a postdoctoral fellow in the Kadoch Lab, on receiving an NCI K99/R00 Pathway-to-Independence Award for his exceptional research and plans for his independent laboratory. Explore more of his work here: bit.ly/4iv3f1m

Sid Jain, a postdoctoral fellow in the Kadoch Lab

030 0

Dana-Farber Cancer Institute @danafarber.bsky.social · 01/10/2026

More than 21,000 women in the U.S. are expected to face an ovarian cancer diagnosis in 2026, according to the National Cancer Institute. As Ovarian Cancer Awareness Month comes to an end, our healing garden is illuminated teal in honor and support of those affected by the disease. 🩵

Dana-Farber Healing Garden lit teal for Ovarian Cancer Awareness Month

030 0

Dana-Farber Cancer Institute @danafarber.bsky.social · 30/09/2026

Our Pediatric Low-Grade Glioma Program is proud to partner with the Richi Foundation and Hopp Children's Cancer Center Heidelberg (KiTZ) on Richi pLGG Cure, a new transatlantic initiative to support children and families affected by pediatric low-grade gliomas (pLGG). Read more: bit.ly/4rKHXiP

020 0

Dana-Farber Cancer Institute @danafarber.bsky.social · 29/09/2026

@lcrf.org recently honored @narjustflorezmd.bsky.social at its 2026 Gala for her tireless efforts to improve patient outcomes through research. Please join us in congratulating her on this recognition. Photo Credit: John Eng Photography

Narjust Florez, MD, FASCO accepting honors at the 2026 Lung Cancer Research Foundation Gala

031 0

Dana-Farber Cancer Institute @danafarber.bsky.social · 21/09/2026

Join us and @pennmedicine.bsky.social for a hybrid CME: The Older Adult with Cancer on Friday, October 16 as we discuss the latest advancements in personalized care and comprehensive assessments for older adults with cancer. Register here: bit.ly/3Usp9IG

The Older Adult with Cancer CME/CNE/MOC-accredited Conference flyer

000 0

Dana-Farber Cancer Institute @danafarber.bsky.social · 19/09/2026

At the @bostonglobe.com Future of Medicine Summit, @drchoueiri.bsky.social joined the panel “How Cancer Vaccines Are Rewriting the Rules of Treatment“ to discuss a new generation of cancer vaccines that have the potential to change the game.

Toni Choueiri, MD, on stage at The Boston Globe Future of Medicine Summit

141 0

Dana-Farber Cancer Institute @danafarber.bsky.social · 18/09/2026

Join us in an overview of the current state and future direction of transplant, cellular, and gene therapies. Gain insights into emerging clinical advances, evolving care delivery models, and opportunities to enhance patient access and outcomes. Register here: bit.ly/4iqt6HN

Stem Cell Transplant and Cellular Therapies Symposium 2026 event details

011 0

Dana-Farber Cancer Institute @danafarber.bsky.social · 18/09/2026

What can we learn from children whose hepatoblastoma progresses or returns? At #SIOP2026, Allison O’Neill, MD, shares findings from the international RELIVE registry examining the presentation and outcomes of progressive and relapsed hepatoblastoma.

030 0

Dana-Farber Cancer Institute @danafarber.bsky.social · 17/09/2026

PROTACs and molecular glues are opening new ways to target proteins that have historically been difficult to reach with conventional drugs. At #SIOP2026, Scott Armstrong, MD, PhD, explores the potential of these emerging approaches in pediatric cancer.

030 0

Dana-Farber Cancer Institute @danafarber.bsky.social · 17/09/2026

How can we continue to improve care for children with metastatic Wilms tumor? At #SIOP2026, Elizabeth Mullen, MD, FAAP, joins the IPSO/PROS/SIOP metastatic Wilms tumor session to discuss the latest thinking in pediatric oncology.

020 0

Dana-Farber Cancer Institute @danafarber.bsky.social · 17/09/2026

Surviving childhood cancer can bring challenges that extend long beyond treatment. At #SIOP2026, Joan Hanania, PhD, joins a panel exploring the experiences and needs of adolescent and young adult survivors as they navigate life after childhood cancer.

020 0

Dana-Farber Cancer Institute @danafarber.bsky.social · 17/09/2026

At #SIOP2026, Alyaa Al-Ibraheemi, MD, explores the molecular landscape of rare, aggressive rhabdomyosarcoma — and how a deeper understanding of tumor biology may help sharpen diagnosis and inform new therapeutic approaches.

020 0

Dana-Farber Cancer Institute @danafarber.bsky.social · 15/09/2026

We are proud to announce that @usnews.com has recognized Dana-Farber/Boston Children's Cancer and Blood Disorders Center as the #1 pediatric cancer program in the nation in its 2026-27 Best Children's Hospitals report. Learn more: bit.ly/4xtRyvJ

Dana-Farber/Boston Children's Cancer and Blood Disorders Center Ranked #1 Pediatric Cancer Program by U.S. News & World Report

Kimberly Stegmaier, MD, on the recognition

083 0

Dana-Farber Cancer Institute @danafarber.bsky.social · 27/08/2026

Join experts in radiation oncology, medical physics, healthcare operations, and cancer center leadership for a multidisciplinary symposium on the emerging role of upright proton therapy. Register before September 4 for early bird pricing: bit.ly/4b682BS

010 0

Dana-Farber Cancer Institute @danafarber.bsky.social · 26/08/2026

The FDA has approved daraxonrasib for adult patients with previously treated metastatic pancreatic cancer based primarily on results from the Dana-Farber-led RASolute 302 trial showing daraxonrasib nearly doubled median overall survival versus chemotherapy. Learn more: bit.ly/46npj6F

Quote from Brian Wolpin, MD, MPH, Director of the Hale Family Center for Pancreatic Cancer Research about the FDA approval of daraxonrasib

0123 0

Dana-Farber Cancer Institute @danafarber.bsky.social · 24/08/2026

We’re pleased to share that Sonal Gandhi has been hired as Senior Vice President (SVP) of Campus Operations and Infrastructure. Please join us in welcoming her, and learn more here: bit.ly/3SOWNYx

030 0

Dana-Farber Cancer Institute @danafarber.bsky.social · 04/08/2026

Dana-Farber Brigham Cancer Center has been recognized as the Best Hospital for Cancer in Massachusetts and ranked #3 in the nation by U.S. News & World Report. Learn more: bit.ly/3TDL9Qi

U.S. News & World Report Best Hospital for Cancer Badge

042 0

Dana-Farber Cancer Institute @danafarber.bsky.social · 28/07/2026

This year, an estimated 17,370 people in the U.S. will be diagnosed with sarcoma, according to @americancancersoc.bsky.social. Our healing garden glowed yellow this July for Sarcoma Awareness Month to honor everyone impacted by the disease and help raise awareness. 🎗️ @dfciayasarcoma.bsky.social

091 0

Dana-Farber Cancer Institute @danafarber.bsky.social · 22/07/2026

Join leaders in radiation oncology, medical physics, healthcare operations, and cancer center administration for a multidisciplinary discussion on the emerging role of upright proton therapy. Learn more and register here: bit.ly/4b682BS

Proton Therapy Symposium hosted at Dana-Farber Cancer Institute

031 0

Dana-Farber Cancer Institute @danafarber.bsky.social · 11/07/2026

In a recent @natcomms.nature.com publication, @drchoueiri.bsky.social highlights how next-generation HIF-2α inhibitor casdatifan shows promising signs of on-target efficacy in first-in-patient clinical trial in metastatic clear cell kidney cancer. Learn more: bit.ly/4gPUbDB

050 0

Dana-Farber Cancer Institute @danafarber.bsky.social · 07/07/2026

Get to know Christine Ryan, MD, whose work in lymphoma care and clinical research is helping drive new therapeutic approaches for patients with mantle cell lymphoma. Learn more about her work: bit.ly/4nPMP4a

030 0

Dana-Farber Cancer Institute @danafarber.bsky.social · 30/06/2026

Could pembrolizumab help improve CAR T-cell therapy outcomes in rare, aggressive B-cell lymphomas? Jennifer Crombie, MD, discusses an ongoing trial exploring this approach before and after CAR T treatment. Learn more about these evolving learnings: bit.ly/4wZiPY2

030 0

Dana-Farber Cancer Institute @danafarber.bsky.social · 27/06/2026

@drmdavids.bsky.social has been selected as the next incumbent of the Harold and Virginia Lash Endowed Chair in Lymphoma Research. Please join us in congratulating him on this well-deserved honor, and in thanking the Lash family for their continued commitment and support.

070 0

Dana-Farber Cancer Institute @danafarber.bsky.social · 25/06/2026

Yesterday, the @fda.gov approved the antibody-drug conjugate sacituzumab govitecan for first-line treatment of metastatic triple-negative breast cancer. This action is based on results from the ASCENT-03 & -04 global clinical trials, which @stolaney1.bsky.social helped to lead. ➡️ bit.ly/4uZoDP0

043 0

Dana-Farber Cancer Institute @danafarber.bsky.social · 23/06/2026

As care for newly diagnosed chronic lymphocytic leukemia continues to advance, clinical trials are playing a key role in expanding treatment possibilities. Inhye Ahn, MD, shares the latest updates and what they could mean for patients: bit.ly/4dIVRLH

030 0

Dana-Farber Cancer Institute @danafarber.bsky.social · 16/06/2026

As treatment in mantle cell lymphoma continues to evolve, clinical and correlative studies are helping shape more targeted strategies for patients. Mark Murakami, MD, shares what this research could mean for care: bit.ly/4dIDdVL

040 0

Dana-Farber Cancer Institute @danafarber.bsky.social · 15/06/2026

We're excited to announce that we received a gift from Trustee Jennifer Perini to strengthen and expand our leadership in pediatric cancer survivorship. The gift establishes the Perini Family Chair in Survivorship and Lisa R. Diller, MD, has been selected as the inaugural incumbent.

060 0

Dana-Farber Cancer Institute @danafarber.bsky.social · 10/06/2026

As treatment options continue to evolve in follicular lymphoma and marginal zone lymphoma, CD3/CD20 bispecific antibodies are showing real promise. Reid Merryman, MD, shares the latest trial updates and what they may mean for patients and clinicians: bit.ly/4dxUqB3

030 0

Dana-Farber Cancer Institute @danafarber.bsky.social · 03/06/2026

Kathleen Keavany, MHA, was recently named senior vice president of Ambulatory Care. This position was newly created to gain strategic leadership and operational oversight of ambulatory services.

050 0

Dana-Farber Cancer Institute @danafarber.bsky.social · 02/06/2026

Research by Lakshmi Nayak, MD, and Caron Jacobson, MD, MMSc, helped advance a major milestone in relapsed/refractory primary CNS lymphoma: an @fda.gov label update for axicabtagene ciloleucel, the first CAR T-cell therapy for this disease. Learn more: bit.ly/4dxSsAF

030 0

Dana-Farber Cancer Institute @danafarber.bsky.social · 01/06/2026

Wrapping up #ASCO26 with Glenn Hanna, MD, delivering phase 1 interim analysis results on emiltatug ledadotin, a targeted antibody-drug conjugate being studied for patients with aggressive adenoid cystic carcinoma.

020 0

Dana-Farber Cancer Institute @danafarber.bsky.social · 31/05/2026

Please join us in congratulating @ireneghobrial.bsky.social and Robert Haddad, MD, on receiving @onclive.bsky.social’s Giants of Cancer Care award — an honor that celebrates the visionaries whose discoveries, innovation, and relentless dedication have transformed the landscape of oncology.

061 0

Dana-Farber Cancer Institute @danafarber.bsky.social · 31/05/2026

Brian Wolpin, MD, MPH, presents results showing a substantial prolongation of survival for patients with previously treated metastatic pancreatic cancer, regardless of RAS mutation status, taking daraxonrasib, an investigational oral RAS(ON) multi-selective inhibitor, compared w/ chemotherapy.

040 0

Dana-Farber Cancer Institute @danafarber.bsky.social · 31/05/2026

In today’s plenary session, Mary-Ellen Taplin, MD, shares positive results from the PROTEUS trial showing patients treated with the apalutamide plus hormone therapy regimen were ten times more likely to have little to no cancer present at surgery. #ASCO26

020 0

Dana-Farber Cancer Institute @danafarber.bsky.social · 31/05/2026

The second day of poster presentations at #ASCO26 spanned research from metastatic hormone-sensitive prostate cancer to non-small cell lung cancer and more. Explore upcoming posters here: bit.ly/3PHFkQm

140 0

Dana-Farber Cancer Institute @danafarber.bsky.social · 31/05/2026

New data from @stolaney1.bsky.social explores how different biomarker subgroups fared in ASCENT-04, which compared sacituzumab govitecan + pembrolizumab with chemotherapy + pembrolizumab in patients with previously untreated PD-L1+ metastatic triple-negative breast cancer. #ASCO26

020 0

Dana-Farber Cancer Institute @danafarber.bsky.social · 31/05/2026

Rishi Surana, MD, PhD, shares initial phase 1 results on NT-175, an engineered T-cell therapy designed to target cancers with the TP53 R175H mutation in patients with advanced solid tumors. #ASCO26

020 0

Dana-Farber Cancer Institute @danafarber.bsky.social · 31/05/2026

Michael Hassett, MD, MPH, presents overall survival results from the eSyM trial, studying whether electronic patient-reported symptom tracking can make a difference in overall survival. #ASCO26

120 0

Dana-Farber Cancer Institute @danafarber.bsky.social · 31/05/2026

We’re back today at #ASCO26. Follow along here and with @danafarbernews.bsky.social as we learn and explore the latest in oncology care and research or join us at our upcoming discussions and poster presentations: bit.ly/4uC0f6o

040 0

Dana-Farber Cancer Institute @danafarber.bsky.social · 30/05/2026

David Reardon, MD, presents phase 1 results in newly diagnosed glioblastoma: NeoVax + pembrolizumab triggered durable anti-tumor immune activity, with median OS of 36.9 vs 25.3 months in MGMT-methylated and 19.0 vs 16.7 months in MGMT-unmethylated disease.

020 0

Dana-Farber Cancer Institute @danafarber.bsky.social · 30/05/2026

Alicia Morgans, MD, MPH, reports that in the first randomized U.S. study of cognitive effects in advanced prostate cancer, darolutamide led to less decline in thinking and memory than enzalutamide over 24 weeks (n=111). #ASCO26

141 0

Dana-Farber Cancer Institute @danafarber.bsky.social · 30/05/2026

New research from @atishchoudhury.bsky.social, MD, PhD, looks at whether treatment can be safely scaled back for certain patients with metastatic prostate cancer who responded exceptionally well to androgen receptor pathway inhibitor therapy. #ASCO26

021 0

Dana-Farber Cancer Institute @danafarber.bsky.social · 30/05/2026

Andrew Wagner, MD, PhD, presents phase 3 PEAK results in advanced GIST: bezuclastinib + sunitinib cut the risk of progression or death by 50% vs sunitinib alone and improved ORR to 46% vs 26% after prior imatinib. #ASCO26

010 0

Dana-Farber Cancer Institute @danafarber.bsky.social · 30/05/2026

New phase 2 data from Julia Rotow, MD, explores safety and efficacy of silevertinib as a first treatment for patients with non-small cell lung cancer with uncommon EGFR mutations. #ASCO26

020 0

Dana-Farber Cancer Institute @danafarber.bsky.social · 30/05/2026

We’re kicking off the day with Suzanne Forrest, MD, discussing phase 2 results for olaparib + ceralasertib in recurrent osteosarcoma, along with biomarker findings that may help explain which patients benefit most. #ASCO26

031 0

Dana-Farber Cancer Institute @danafarber.bsky.social · 30/05/2026

#ASCO26 continues today! Follow along here and with @danafarbernews as we learn and explore the latest in oncology care and research, join us at our upcoming discussions or poster presentations, and stop by booth 10007: bit.ly/4uC0f6o

020 0

Dana-Farber Cancer Institute @danafarber.bsky.social · 29/05/2026

Wrapping up day one of #ASCO26 with Paul G. Richardson, MD, sharing phase 3 trial results for patients with relapsed or refractory multiple myeloma, the addition of the oral drug mezigdomide to standard treatment with carfilzomib and dexamethasone markedly improved progression-free survival.

140 0

Dana-Farber Cancer Institute @danafarber.bsky.social · 29/05/2026

@chrismanzmd.bsky.social discusses a pilot study on using AI to create clear summaries of difficult hospital conversations, with the goal of improving care for seriously ill patients.

010 0